

September 29, 2010  
AnGes MG, Inc.

Basic Patent for HVJ-E Granted in the US  
- Covering Exogenous Gene Transfer Methods -

AnGes MG, Inc. is pleased to announce that a basic patent which covers exogenous gene transfer methods with HVJ-E (Hemagglutinating Virus of Japan [also Sendai Virus]-Envelope) vector was granted in the US, and that the registration of this patent was made public (US7,803,621) yesterday (September 28, 2010).

In basic researches on gene therapy and life science, it is necessary to use some kind of vector to increase the efficiency of gene transfer into cells.

Virus vectors such as adenovirus or liposome are conventionally used, but there have been many problems and concerns such as pathogenicity and toxicity, which have become obstacles to advances in healthcare and researches.

This invention is an innovative vector technology that focuses on the excellent membrane-fusing capacity of Sendai Virus, and is free of pathogenicity and toxicity related problems since it uses inactivated virus envelopes.

AnGes MG and its subsidiary GenomIdea Inc. have been jointly developing this invention, and have applied for patents for various uses and manufacturing methods including this basic patent.

In particular, this basic patent forms the basis of the HVJ-E project, and is now registered in the US, which has the largest market in the world.

Regarding the global development of the HVJ-E project, AnGes MG has registered patents in Japan, Europe, Canada, Australia, China, South Korea, Taiwan, etc. in addition to the US, and has established its own patent network.

This invention is already commercially available in Japan and the US as a highly-efficient transfection kit “GenomONE®”. It was realized through the cooperation of Ishihara Sangyo Kaisha, Ltd. and AnGes MG, and is widely used in life science researches.

Meanwhile, this trend will have no effect on AnGes MG’s business performance for the current fiscal year.